Study S000954

Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02541734
Acronym: GLP1-EX-GELO
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 12
Start: 2015-08
Primary completion: 2017-05
Lead sponsor: Radboud University Medical Center
Conditions: Diabetes Mellitus, Non-Insulin-Dependent; Diabetes Mellitus
Interventions: DRUG:Gelofusine; RADIATION:111In-exendin 4 SPECT/CT; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2014-003006-33; NIH:2014

Registered primary outcomes

Renal uptake as measured by uptake of 111In-exendin-4 on SPECT images and without co-infusion of Gelofusine. [up to 8 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.